Edwards Lifesciences Corporation (NYSE:EW) had an volatile session and gained 0.21 points till last call. The price was at $101.73, gaining 0.21% till the last intraday data. The total uptick value was $14.05 million while the total downtick value was $17.11 million. The shares saw a net money flow of $(-3.06) million and the up/down ratio stood at 0.82. The stock has seen a change of of 0.2% for the week. The share had a block transaction during the course of trading in which the net money flow was $(-2.33) million. Almost $0 million were received in upticks and approximately $2.33 million were lost in downticks, thereby giving the up/down ratio of 0.
Currently the company Insiders own 2.37% of Edwards Lifesciences Corporation shares according to the proxy statements. Institutional Investors own 87.59% of Edwards Lifesciences Corporation shares. On the companys insider trading activities, The director officer (Chairman & CEO), of Edwards Lifesciences Corp, Mussallem Michael A had unloaded 49,100 shares at $102.25 per share in a transaction on June 8, 2016. The total value of transaction was $5,020,475. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Edwards Lifesciences Corporation (NYSE:EW) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.39 points or 0.38% at $101.13 with 865,296 shares getting traded. Post opening the session at $101.22, the shares hit an intraday low of $100.91 and an intraday high of $102.55 and the price was in this range throughout the day. The company has a market cap of $21,416 million and the number of outstanding shares have been calculated to be 211,762,740 shares. The 52-week high of Edwards Lifesciences Corporation (NYSE:EW) is $112 and the 52-week low is $62.53.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Edwards Lifesciences Corporation (NYSE:EW). The current rating of the shares is Neutral, according to the research report released by the firm. The rating by the firm was issued on June 9, 2016.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.